328 related articles for article (PubMed ID: 18061495)
21. Expression of E-cadherin, P-cadherin and beta-catenin in canine malignant mammary tumours in relation to clinicopathological parameters, proliferation and survival.
Gama A; Paredes J; Gärtner F; Alves A; Schmitt F
Vet J; 2008 Jul; 177(1):45-53. PubMed ID: 17631398
[TBL] [Abstract][Full Text] [Related]
22. Expression and prognostic significance of CK19 in canine malignant mammary tumours.
Gama A; Alves A; Schmitt F
Vet J; 2010 Apr; 184(1):45-51. PubMed ID: 19264518
[TBL] [Abstract][Full Text] [Related]
23. Increased expression of C5a receptor (CD88) mRNA in canine mammary tumors.
Hezmee MN; Kyaw-Tanner M; Lee JY; Shiels IA; Rolfe B; Woodruff T; Mills PC
Vet Immunol Immunopathol; 2011 Jan; 139(1):50-6. PubMed ID: 20846729
[TBL] [Abstract][Full Text] [Related]
24. The role of Cox-2 expression in the prognosis of dogs with malignant mammary tumours.
Queiroga FL; Pires I; Lobo L; Lopes CS
Res Vet Sci; 2010 Jun; 88(3):441-5. PubMed ID: 19939424
[TBL] [Abstract][Full Text] [Related]
25. Lymphocyte infiltration, expression of interleukin (IL) -1, IL-6 and expression of mutated breast cancer susceptibility gene-1 correlate with malignancy of canine mammary tumours.
Kim JH; Yu CH; Yhee JY; Im KS; Sur JH
J Comp Pathol; 2010; 142(2-3):177-86. PubMed ID: 19959182
[TBL] [Abstract][Full Text] [Related]
26. Telomerase reverse transcriptase (TERT) expression in canine mammary tissues: a specific marker for malignancy?
Zavlaris M; Angelopoulou K; Vlemmas I; Papaioannou N
Anticancer Res; 2009 Jan; 29(1):319-25. PubMed ID: 19331168
[TBL] [Abstract][Full Text] [Related]
27. Investigation of the local expression of the relaxin system in canine mammary tumours.
Lamp O; Honscha KU; Jakob J; Lamp J; Schweizer S; Reischauer A; Gottschalk J; Hahn A; Ebert M; Rothemund S; Blaschzik S; Einspanier A
Reprod Domest Anim; 2009 Jul; 44 Suppl 2():224-9. PubMed ID: 19754574
[TBL] [Abstract][Full Text] [Related]
28. Comparison of steroid receptor expression in normal, dysplastic, and neoplastic canine and feline mammary tissues.
Millanta F; Calandrella M; Bari G; Niccolini M; Vannozzi I; Poli A
Res Vet Sci; 2005 Dec; 79(3):225-32. PubMed ID: 16054892
[TBL] [Abstract][Full Text] [Related]
29. Mutations of p53 tumor suppressor gene in spontaneous canine mammary tumors.
Lee CH; Kweon OK
J Vet Sci; 2002 Dec; 3(4):321-5. PubMed ID: 12819382
[TBL] [Abstract][Full Text] [Related]
30. Proliferative activity, apoptosis and expression of oestrogen receptor and Bcl-2 oncoprotein in canine mammary gland tumours.
Yang WY; Liu CH; Chang CJ; Lee CC; Chang KJ; Lin CT
J Comp Pathol; 2006 Jan; 134(1):70-9. PubMed ID: 16423573
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical expression of caveolin-1 in normal and neoplastic canine mammary tissue.
Amorim I; Lopes CC; Faustino AM; Pereira PD
J Comp Pathol; 2010 Jul; 143(1):39-44. PubMed ID: 20153867
[TBL] [Abstract][Full Text] [Related]
32. An assessment of the clonality of the components of canine mixed mammary tumours by mitochondrial DNA analysis.
Bertagnolli AC; Soares P; van Asch B; Amorim A; Cirnes L; Máximo V; Cassali GD
Vet J; 2009 Nov; 182(2):269-74. PubMed ID: 18752974
[TBL] [Abstract][Full Text] [Related]
33. Influence of catechol-O-methyltransferase (COMT) genotypes on the prognosis of canine mammary tumors.
Dias Pereira P; Lopes CC; Matos AJ; Pinto D; Gärtner F; Lopes C; Medeiros R
Vet Pathol; 2009 Nov; 46(6):1270-4. PubMed ID: 19605895
[TBL] [Abstract][Full Text] [Related]
34. MUC1 expression in canine malignant mammary tumours and relationship to clinicopathological features.
de Oliveira JT; Pinho SS; de Matos AJ; Hespanhol V; Reis CA; Gärtner F
Vet J; 2009 Dec; 182(3):491-3. PubMed ID: 18948041
[TBL] [Abstract][Full Text] [Related]
35. Expression patterns of connexin 26 and connexin 43 mRNA in canine benign and malignant mammary tumours.
Gotoh H; Harada K; Suzuki K; Hashimoto S; Yamamura H; Sato T; Fukumoto K; Hagiwara H; Ishida T; Yamada K; Asano R; Yano T
Vet J; 2006 Jul; 172(1):178-80. PubMed ID: 16772144
[TBL] [Abstract][Full Text] [Related]
36. Metallothionein expression in benign and malignant canine mammary gland tumours.
Erginsoy SD; Sozmen M; Caldin M; Furlanello T
Res Vet Sci; 2006 Aug; 81(1):46-50. PubMed ID: 16289156
[TBL] [Abstract][Full Text] [Related]
37. Gene expressions of canine angiopoietin-1 and -2 in normal tissues and spontaneous tumours.
Kato Y; Asano K; Mizutani I; Konno T; Sasaki Y; Kutara K; Teshima K; Edamura K; Kano R; Suzuki K; Shibuya H; Sato T; Hasegawa A; Tanaka S
Res Vet Sci; 2006 Oct; 81(2):280-6. PubMed ID: 16545849
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of FOXP3 expression in canine mammary gland tumours.
Oh SY; Ryu HH; Yoo DY; Hwang IK; Kweon OK; Kim WH
Vet Comp Oncol; 2014 Mar; 12(1):20-8. PubMed ID: 22541038
[TBL] [Abstract][Full Text] [Related]
39. Identification of genetic variation in 11 candidate genes of canine mammary tumour.
Borge KS; Børresen-Dale AL; Lingaas F
Vet Comp Oncol; 2011 Dec; 9(4):241-50. PubMed ID: 22077404
[TBL] [Abstract][Full Text] [Related]
40. Role of steroid hormones and prolactin in canine mammary cancer.
Queiroga FL; Pérez-Alenza MD; Silvan G; Peña L; Lopes C; Illera JC
J Steroid Biochem Mol Biol; 2005 Feb; 94(1-3):181-7. PubMed ID: 15862964
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
